MetaVia Inc. (NASDAQ:MTVA) Stock Short Interest Falls 36.0%

MetaVia Inc. (NASDAQ:MTVA) was the recipient of a large decrease in short interest in the month of September. As of September 30th, there was short interest totaling 117,409 shares, a decrease of 36.0% from the September 15th total of 183,472 shares. Based on an average daily volume of 57,790 shares, the short-interest ratio is presently 2.0 days. Currently, 2.3% of the company’s stock are sold short.

MetaVia Price Performance

Shares of MTVA stock opened at $1.26 on Friday. MetaVia has a 1-year low of $0.97 and a 1-year high of $14.85. The stock’s 50-day moving average is $1.57 and its 200 day moving average is $1.66. The company has a market cap of $6.50 million, a P/E ratio of -0.39 and a beta of 0.96.

MetaVia (NASDAQ:MTVA) last posted its earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.08). On average, analysts anticipate that MetaVia will post -2.79 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on MTVA. HC Wainwright reiterated a “buy” rating on shares of MetaVia in a research note on Friday, July 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of MetaVia in a research note on Tuesday, July 21st. Finally, Wall Street Zen upgraded MetaVia to a “sell” rating in a report on Saturday, June 20th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $20.00.

About MetaVia

MetaVia, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and other metabolic diseases. The company’s programs are designed to address conditions including excess weight, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH), a form of fatty liver disease associated with metabolic dysfunction.

MetaVia’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being developed as a potential treatment for obesity and related metabolic complications.